Myriad Genetics (MYGN) AI Stock Analysis

• Market Cap: $602.16M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: 0.21%
• EPS Growth: -233.51%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.00
• Shares Outstanding: 93,213,720
• 10 Day Avg. Volume: 1,177,729
• 30 Day Avg. Volume: 1,076,012
• PEG Ratio: 0.18
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 1.48
• P/FCF Ratio: -32.35
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: 0.89
• Enterprise Value/Gross Profit: 1.26
• Enterprise Value/Ebitda: -2.08
• 1Y Price Target: $8.20
• Price Target Upside: 29.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): <0.01
• Revenue Forecast (FY): $821.69M

• Rating: 51 Neutral
• Price Target: $8.00 ▲(26.38% Upside)

Myriad Genetics faces significant financial challenges, particularly in profitability and cash flow management, which weigh heavily on its overall score. Technical analysis provides a moderately positive outlook, but valuation remains a concern due to ongoing losses. The company's strategic initiatives and operational efficiencies offer some optimism for future growth.

Positive Factors

Strategic Partnerships

This partnership enhances Myriad's capabilities in precision medicine, potentially expanding its market reach and strengthening its competitive position in the genetic testing industry.

Product Launches

New product launches are expected to drive growth by expanding Myriad's test offerings, potentially increasing market share and revenue in the competitive genetic testing market.

Operational Efficiency

High gross margins indicate effective cost management and operational efficiency, which can contribute to long-term profitability and financial stability.

Negative Factors

Profitability Challenges

Persistent profitability issues indicate difficulty in converting revenue into profit, which may hinder long-term financial health and investment capacity.

Cash Flow Issues

Negative cash flows suggest inefficiencies in cash generation, which can limit the company's ability to fund operations and invest in growth opportunities.

Revenue Decline

A decline in revenue signals potential market challenges and could impact the company's ability to sustain growth and profitability in the long term.

Myriad Genetics Business Overview & Revenue Model

Company Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Myriad Genetics generates revenue primarily through the sale of its genetic testing services. The company operates a fee-for-service model, where healthcare providers order tests for patients, and Myriad bills the insurers or patients directly. Key revenue streams include the hereditary cancer testing segment, which assesses genetic mutations in patients to evaluate their cancer risk, and the myRisk test that evaluates multiple cancer types simultaneously. Additionally, Myriad earns income from its pharmacogenomic tests that help determine how patients metabolize certain medications, enhancing treatment efficacy. The company has also established significant partnerships with various healthcare organizations and payers, which facilitates broader access to its tests and enhances its market presence. Factors contributing to earnings include increasing awareness and demand for genetic testing, advancements in technology, and the growing emphasis on personalized medicine.

Myriad Genetics Financial Statement Overview

Summary

Myriad Genetics shows strong revenue growth but struggles with profitability and cash flow management. The company has a solid gross profit margin, but negative net margins and cash flows indicate ongoing operational and financial hurdles. Moderate leverage is present, but negative return on equity suggests inefficiencies in generating returns.

Income Statement

Myriad Genetics shows a mixed performance in its income statement. The company has experienced a positive revenue growth rate of 19.2% in the TTM, indicating strong top-line growth. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin remains healthy at over 70%, but the significant negative net profit margin of -47.4% highlights ongoing challenges in controlling costs and achieving profitability.

Balance Sheet

The balance sheet of Myriad Genetics reflects moderate leverage with a debt-to-equity ratio of 0.40 in the TTM, which is manageable. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly provided, but the company's equity position appears stable relative to its assets.

Cash Flow

The cash flow statement reveals challenges in cash generation, with negative operating and free cash flows in the TTM. Despite a significant improvement in free cash flow growth, the operating cash flow to net income ratio is negative, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	832.90M	837.60M	753.20M	678.40M	690.60M	557.00M
Gross Profit	586.70M	585.40M	517.00M	476.40M	493.00M	378.80M
EBITDA	-355.00M	-59.50M	-186.10M	-67.80M	14.10M	-123.40M
Net Income	-395.20M	-127.30M	-263.30M	-112.00M	-27.20M	-223.70M
Balance Sheet
Total Assets	677.30M	1.03B	1.15B	1.20B	1.32B	1.42B
Cash, Cash Equivalents and Short-Term Investments	74.40M	102.40M	140.90M	114.90M	339.80M	150.70M
Total Debt	154.60M	140.30M	152.10M	145.00M	92.30M	0.00
Total Liabilities	289.20M	326.50M	363.30M	312.90M	352.90M	537.80M
Stockholders Equity	388.10M	701.10M	783.20M	885.80M	967.80M	881.00M
Cash Flow
Free Cash Flow	-50.00M	-38.40M	-184.20M	-151.60M	600.00K	-40.10M
Operating Cash Flow	-22.60M	-8.70M	-110.90M	-106.30M	18.60M	-26.90M
Investing Cash Flow	-13.60M	-11.90M	31.90M	-77.50M	274.40M	61.60M
Financing Cash Flow	15.20M	-7.40M	152.90M	-8.00M	-150.60M	-1.00M

Myriad Genetics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYGN, the sentiment is Negative. The current price of 6.33 is below the 20-day moving average (MA) of 7.74, below the 50-day MA of 7.51, and below the 200-day MA of 7.50, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 31.88 is Neutral, neither overbought nor oversold. The STOCH value of 11.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYGN.

Myriad Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	64 Neutral	$850.18M	12.59	24.11%	―	14.46%	―
CSTL	62 Neutral	$979.86M	―	-2.69%	―	10.15%	-295.52%
FLGT	61 Neutral	$700.33M	―	-4.54%	―	4.31%	69.57%
NEO	53 Neutral	$1.31B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$602.16M	―	-72.52%	―	0.21%	-233.51%
PSNL	51 Neutral	$775.26M	―	-43.69%	―	-21.02%	47.74%

Myriad Genetics Corporate Events

Myriad Genetics Reports Q3 2025 Financial Results

Myriad Genetics is a prominent player in the molecular diagnostic testing and precision medicine industry, offering a range of tests that assess disease risk and guide treatment decisions. In its third quarter of 2025, Myriad Genetics reported a revenue of $205.7 million, marking a 4% decrease from the previous year, although revenue remained stable when excluding specific headwinds. The company saw growth in hereditary cancer testing, with revenue and volume increasing by 3% and 11% year-over-year, respectively, and maintained a gross margin of 69.9%. Despite a GAAP net loss of $27.4 million, the adjusted earnings per share broke even, and adjusted EBITDA was reported at $10.3 million. A notable strategic move was the collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic testing solution. Myriad Genetics also highlighted its efforts to enhance profitability by focusing on the Cancer Care Continuum and implementing organizational changes to improve customer experience and market share. Looking ahead, Myriad Genetics remains committed to its financial guidance for 2025, aiming to continue its strategic initiatives and maintain its position in the industry.

Myriad Genetics Advances in Metastatic Cancer Treatment Study

Myriad Genetics (MYGN) is collaborating on a clinical study titled SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives. The study aims to evaluate the safety of a novel treatment for metastatic cancer in patients with BRCA1, BRCA2, or PALB2 mutations, which could significantly impact treatment options for these genetic conditions.

Myriad Genetics Finalizes CFO Separation Agreement

On October 1, 2025, Myriad Genetics entered into a Separation Agreement with its former CFO, Scott J. Leffler, following his departure on August 15, 2025, and official separation on September 2, 2025. The agreement, effective October 9, 2025, includes a severance payment of $1,239,384 and accelerated vesting of equity awards, reflecting the company’s adherence to standard executive transition practices and potentially impacting its financials and leadership dynamics.

The most recent analyst rating on (MYGN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.

Myriad Genetics Announces Leadership Change in Accounting

On September 29, 2025, Myriad Genetics announced the resignation of Natalie Munk, their Senior Vice President and Chief Accounting Officer, effective October 24, 2025. Her departure was not due to any disagreements with the company. In response, the company appointed Benjamin R. Wheeler, their current Chief Financial Officer, as the new principal accounting officer effective upon Munk’s departure. Wheeler, who has been with the company for over thirteen years in various financial roles, will not receive additional compensation for this new designation.

The most recent analyst rating on (MYGN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.

Myriad Genetics Appoints Ben R. Wheeler as CFO

On August 18, 2025, Myriad Genetics announced the appointment of Ben R. Wheeler as the new Chief Financial Officer, effective August 16, 2025, following the departure of Scott J. Leffler from the role. Wheeler, who has been with the company for over 13 years, brings extensive financial expertise and leadership experience, which is expected to support Myriad’s growth strategy. The company also reaffirmed its financial guidance for the full year 2025, indicating confidence in its strategic direction.

The most recent analyst rating on (MYGN) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.

Myriad Genetics’ Earnings Call: Growth Amid Challenges

Myriad Genetics’ recent earnings call conveyed a generally positive sentiment, underscored by robust revenue growth, profitability, and strategic partnerships. Despite challenges, such as UnitedHealthcare’s coverage decision impacting GeneSight and issues in prenatal testing, the company demonstrated confidence by raising its guidance for 2025, signaling a strong strategic direction.

Myriad Genetics Updates 2025 Revenue Guidance Amid Growth

Myriad Genetics is a prominent company in the molecular diagnostic testing and precision medicine sector, focusing on developing tests that assess disease risk and guide treatment decisions across various medical specialties. The company recently reported its second quarter 2025 financial results, highlighting a slight revenue increase and an updated revenue guidance for the year. Despite a GAAP net loss due to impairment charges, Myriad Genetics saw growth in its hereditary cancer testing and improved gross margins.